Advance on stem cells therapy for bronchopulmonary dysplasia / 中华实用儿科临床杂志

ABSTRACT

The postnatal lung contains populations of stem cells with the capacity to reconstitute the lung after injury.Prematurity and its antecedent factors may alter lung stem cell programming leading to dysfunctional repair.Preterm infants who develop bronchopulmonary dysplasia exhibit decreased and/or dysfunctional stem cells.Preclinical studies provide robust evidence that stem cells reduce lung injury and improve survival in experimental models of bronchopulmonary dysplasia via paracrine-mediated mechanisms.Mesenchymal stem cells are an attractive population for lung repair as they are immunoprivileged, easily isolated, and have pleiotropic therapeutic effects.Early clinical evidence demonstrates the safety and feasibility of mesenchymal stem cell therapy for bronchopulmonary dysplasia.However, barriers for implementation, including optimal dosing, patient, timing, and culture techniques, need to be overcome for successful translation.